Summary

United States of America (USA) Generics Market Summary, Competitive Analysis and Forecast, 2017-2026

Summary

Generics in the United States industry profile provides top-line qualitative and quantitative summary information including: market share, market size (value and volume 2017-21, and forecast to 2026). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.

Key Highlights

- For the purposes of this profile, a generic drug is defined as a copy of an ethical (prescription) drug formerly protected by patents that have now expired. Both unbranded generics and all branded generics are included. However, off-patent drugs that continue to be offered by the original manufacturer under the original name, and which form part of the 'generic-eligible' market, are not included.
- The US generics market had total revenues of $65.0 billion in 2021, representing a compound annual growth rate (CAGR) of 1% between 2016 and 2021.
- Market consumption volume increased with a CAGR of 0.1% between 2016 and 2021, to reach a total of 90.5 % in 2021.
- Over the past five years, the US market recorded growth of 1%. Growth in the market has been driven by demographic trends as the US population continues to grow older.

Scope

- Save time carrying out entry-level research by identifying the size, growth, major segments, and leading players in the generics market in the United States
- Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the generics market in the United States
- Leading company profiles reveal details of key generics market players’ global operations and financial performance
- Add weight to presentations and pitches by understanding the future growth prospects of the United States generics market with five year forecasts by both value and volume

Reasons to Buy

- What was the size of the United States generics market by value in 2021?
- What will be the size of the United States generics market in 2026?
- What factors are affecting the strength of competition in the United States generics market?
- How has the market performed over the last five years?
- Who are the top competitors in the United State's generics market?

ページTOPに戻る

Table of Contents

Table of Contents
1 Executive Summary
1.1. Market value
1.2. Market value forecast
1.3. Market volume
1.4. Market volume forecast
1.5. Geography segmentation
1.6. Market rivalry
1.7. Competitive Landscape
2 Market Overview
2.1. Market definition
2.2. Market analysis
3 Market Data
3.1. Market value
3.2. Market volume
4 Market Segmentation
4.1. Geography segmentation
5 Market Outlook
5.1. Market value forecast
5.2. Market volume forecast
6 Five Forces Analysis
6.1. Summary
6.2. Buyer power
6.3. Supplier power
6.4. New entrants
6.5. Threat of substitutes
6.6. Degree of rivalry
7 Competitive Landscape
7.1. Who are the leading players?
7.2. What are the strengths/weaknesses of the leading players?
7.3. Has there been any significant recent M&A activity?
7.4. How did the COVID-19 pandemic impact leading players?
8 Company Profiles
8.1. Teva Pharmaceutical Industries Limited
8.2. Viatris Inc.
8.3. Pfizer Inc.
9 Macroeconomic Indicators
9.1. Country data
10 Appendix
10.1. Methodology
10.2. Industry associations
10.3. Related MarketLine research
10.4. About MarketLine